Channing Paller (@cpaller) 's Twitter Profile
Channing Paller

@cpaller

Medical oncologist at Johns Hopkins specializing in clinical trials and urologic oncology. Views are my own.

ID: 62276578

calendar_today02-08-2009 15:09:59

23 Tweet

245 Followers

28 Following

Nima Sharifi (@nimasharifimd) 's Twitter Profile Photo

Great presentations & discussion of QOL & AEs for hormonal tx options w/ biochemical recurrence ⁦Stephen Freedland, MD⁩ ⁦Ronald Chen⁩ ⁦Channing Paller⁩. Bottom line is AEs differ substantially w/ single agent and combos approaches. Don’t give triple tx. ⁦ASCO⁩ #asco24

Great presentations &amp; discussion of QOL &amp; AEs for hormonal tx options w/ biochemical recurrence ⁦<a href="/SFreedlandMD/">Stephen Freedland, MD</a>⁩ ⁦<a href="/RonaldChenMD/">Ronald Chen</a>⁩ ⁦<a href="/Cpaller/">Channing Paller</a>⁩. Bottom line is AEs differ substantially w/ single agent and combos approaches. Don’t give triple tx. ⁦<a href="/ASCO/">ASCO</a>⁩ #asco24
Channing Paller (@cpaller) 's Twitter Profile Photo

In men with localized prostate cancer, a recent study found, primary androgen deprivation therapy should be reserved for high-risk patients.

Channing Paller (@cpaller) 's Twitter Profile Photo

ASCO update: Early chemotherapy for men with newly diagnosed extensive metastatic prostate cancer improves survival. nyti.ms/1kllhze

Channing Paller (@cpaller) 's Twitter Profile Photo

Biden asks oncologists to make clinical trials available to 96% of cancer patients who are not treated on studies. gumdroptrials.org